M. Livermore, M. Warner, S. Mushtaq; Hlth. Protection Agency, Lon- don, United Kingdom. coli K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, N. Jones; JMI Lab., N Liberty, IA. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, N. Jones; J

200 SCIENTIFIC SESSIONS September 9-12 | F-2045 DS-8587, a New Generation of Broad Spectrum Quinolone: In Vitro Antibacterial Activity against 9 Major Anaerobic Species of Japanese Clinical Isolates

H. Mikamo

1 , Y. Yamagishi 1 , H. Suematsu 1 , H. Sawamura 1 , M. Chiba 2 , R. Okumura 2 , K. Hoshino 2 ; 1 Aichi Med. Univ., Aichi, Japan, 2 Daiichi Sankyo, Co. Ltd., Tokyo, Japan. F-2046 In Vitro Activity of KPI-10 against Clinically Important Gram-Negative Bacteria

J. Deane

1 , A. Simenauer 1 , Y. Ge 2 , P. B. Eckburg 2 , D. Sahm 1 ; 1 Eurofins, Chantilly, VA, 2 Kalidex Pharmaceuticals, Inc., Menlo Park, CA. F-2047 In Vitro Activity of KPI-10 against Clinically Important Gram-Positive Bacteria

J. Deane

1 , A. Simenauer 1 , Y. Ge 2 , P. Eckburg 2 , D. Sahm 1 ; 1 Eurofins, Chan- tilly, VA, 2 Kalidex Pharmaceuticals Inc., Menlo Park, CA. F-2048 Activity of Novel Fluoroquinolone, KPI-10, vs. Multidrug- Resistant Bacteria, Including those with NDM-1 Carbapenemase

D. M. Livermore, M. Warner, S. Mushtaq; Hlth. Protection Agency, Lon- don, United Kingdom.

F-2049 In Vitro Activity and DNA Gyrase Inhibitory Activity of KPI-10, a Novel Fluoroquinolone FQ, against Quinolone- Susceptible QS and Quinolone-Resistant QR

E. coli

D. Kazamori, K. Sugimoto, Diploma, H. Aoi, K. Itoh, Y. Kuramoto, A. Yazaki; Wakunaga Pharmaceutical Co. Ltd., Hiroshima, Japan. F-2050 In Vitro Activity of KPI-10 Tested against a Global Collection of Acinetobacter spp. Including Multidrug-Resistant MDR Strains R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2051 KPI-10 In Vitro Activity Tested against Pathogens Common- ly Associated with Community-Acquired Bacterial Pneumonia CABP Infections R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2052 KPI-10, a Novel Flouroquinolone FQ Tested against Neisseria gonorrhoeae Including Ciprofloxacin Non-Susceptible CIP-NS and Penicillin Non-Susceptible PEN-NS Strains R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2053 In Vitro Activity of KPI-10 Tested against Pathogens Commonly Associated with Urinary Tract infections UTIs R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2054 Activity of KPI-10 against Highly Resistant E. coli and

K. pneumoniae from Various Countries

M. A. Habeeb 1 , P. Eckburg 2 , J. Ge 3 , C. G. Giske 4 ; 1 Natl. Inst. for Biotech- nology and Genetic Engineering NIBGE, Faisalabad, Pakistan, 2 Kalidex Pharmaceutical Inc, Menlo Park, CA, 3 Kalidex Pharmaceuticals, Menlo Park, CA, 4 Karolinska Inst., Stockholm, Sweden. F-2055 In Vivo Activity of KPI-10, a Novel Fluoroquinolone FQ, in Mouse Systemic and Local Infection Models Caused by Multidrug- and FQ-Resistant Pathogens H. Amano, H. Aoi, K. Sakata, K. Inokuma, D. Kazamori, K. Itoh, Y. Kuramoto, A. Yazaki; Wakunaga Pharmaceutical Co. Ltd., Akitakata, Japan. F-2056 50 Effective Dose ED50 Determination of KPI-10 for Treating Sepsis in Mice Due to Quinolone-Susceptible QS and Quinolone-Resistant QR Nosocomial Pathogens: Comparison with Ciprofloxacin CIP

C. Jacqueline